Bristol-Myers Squibb Co
BMY46.350USD
+0.150+0.32%
Close 09/15, 16:00（ET）Quotes delayed by 15 min
94.32BMarket Cap
18.68P/E TTM
More Details of Bristol-Myers Squibb Co Company
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Company Info
Ticker SymbolBMY
Company nameBristol-Myers Squibb Co
IPO dateMar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Number of employees34100
Security typeOrdinary Share
Fiscal year-endMar 17
AddressRoute 206 And Province Line Road
CityPRINCETON
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code08543
Phone16092524621
Websitehttps://www.bms.com
Ticker SymbolBMY
IPO dateMar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
8.84K
+6.22%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Other
3.00B
26.76%
By RegionUSD
Name
Revenue
Proportion
United States
7.87B
70.29%
International
3.11B
27.77%
other
218.00M
1.95%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Eliquis
3.56B
31.83%
Opdivo
2.27B
20.30%
Revlimid
936.00M
8.36%
Orencia
770.00M
6.87%
Pomalyst/Imnovid
659.00M
5.88%
Other
3.00B
26.76%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Global Advisors (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
Other
74.14%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Global Advisors (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
Other
74.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.68%
Investment Advisor/Hedge Fund
25.41%
Research Firm
2.90%
Pension Fund
2.54%
Bank and Trust
2.27%
Sovereign Wealth Fund
1.75%
Hedge Fund
1.14%
Insurance Company
0.16%
Family Office
0.06%
Other
17.09%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
4180
1.70B
83.46%
+31.40M
2025Q1
4287
1.68B
82.63%
+10.66M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
190.47M
9.36%
+1.45M
+0.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
97.77M
4.8%
+752.85K
+0.78%
Mar 31, 2025
State Street Global Advisors (US)
94.83M
4.66%
-310.27K
-0.33%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
60.61M
2.98%
+306.43K
+0.51%
Mar 31, 2025
JP Morgan Asset Management
69.89M
3.43%
+6.79M
+10.76%
Mar 31, 2025
Capital International Investors
66.47M
3.27%
+20.60M
+44.91%
Mar 31, 2025
Geode Capital Management, L.L.C.
45.45M
2.23%
+1.06M
+2.39%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
29.03M
1.43%
+534.70K
+1.88%
Mar 31, 2025
Wellington Management Company, LLP
23.73M
1.17%
+17.75M
+296.96%
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
First Trust NASDAQ Pharmaceuticals ETF
5.91%
LSV Disciplined Value ETF
4.06%
iShares U.S. Pharmaceuticals ETF
3.88%
Coastal Compass 100 ETF
3.81%
Schwab U.S. Dividend Equity ETF
3.57%
Cullen Enhanced Equity Income ETF
3.33%
SPDR S&P Pharmaceuticals ETF
3.26%
Tema Oncology ETF
3.16%
VanEck Pharmaceutical ETF
3.1%
Brookstone Value Stock ETF
3%
View more
First Trust NASDAQ Pharmaceuticals ETF
Proportion5.91%
LSV Disciplined Value ETF
Proportion4.06%
iShares U.S. Pharmaceuticals ETF
Proportion3.88%
Coastal Compass 100 ETF
Proportion3.81%
Schwab U.S. Dividend Equity ETF
Proportion3.57%
Cullen Enhanced Equity Income ETF
Proportion3.33%
SPDR S&P Pharmaceuticals ETF
Proportion3.26%
Tema Oncology ETF
Proportion3.16%
VanEck Pharmaceutical ETF
Proportion3.1%
Brookstone Value Stock ETF
Proportion3%
Dividend
A total of
22.71B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
